AIMS/HYPOTHESIS: We sought to identify determinants of progression from impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) to diabetes in high-risk screened individuals. METHODS: In general practices in Denmark, stepwise screening for type 2 diabetes mellitus in persons aged 40 to 69 years included a risk questionnaire, random blood glucose, HbA1c, fasting blood glucose and an OGTT. The 1,821 individuals with IGT or isolated IFG (WHO 1999) were re-invited after 1 and 3 years. Follow-up data on glucose measurements were available in 1,510 individuals and additional clinical data in 1,002 collected at the 3-year visits. Regression models using interval censoring were used. RESULTS: Progression rates from IFG and IGT to diabetes over 3.5 years were 11.8 and 17.0 per 100 person-years, respectively and were particularly high in the first year. Baseline determinants of progression were: IFG: glucose measures, BMI [per kg/m2, rate ratio (RR) 1.04 (95% CI, 1.01-1.08)] and triacylglycerol [per twofold increase, RR 2.19 (1.49-3.22)]; and IGT: glucose measures and known hypertension [RR 1.46 (1.11-1.93)]. Weight reduction and decreased triacylglycerol were inversely associated with development of diabetes in IFG individuals [per 1 kg/year, RR 0.81 (0.66-0.98) and per 1 mmol l(-1) year(-1), RR 0.08 (0.01-0.51), respectively], whereas in IGT participants only weight reduction was inversely associated [per 1 kg/year, RR 0.80 (0.67-0.96)]. CONCLUSIONS/ INTERPRETATION: Higher levels of glucose measures, larger BMI, known hypertension and hypertriacylglycerolaemia are significant determinants of progression in high-risk screened individuals. Weight loss of 1 kg/year or reduction of hypertriacylglycerolaemia markedly reduced the risk of diabetes.
AIMS/HYPOTHESIS: We sought to identify determinants of progression from impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) to diabetes in high-risk screened individuals. METHODS: In general practices in Denmark, stepwise screening for type 2 diabetes mellitus in persons aged 40 to 69 years included a risk questionnaire, random blood glucose, HbA1c, fasting blood glucose and an OGTT. The 1,821 individuals with IGT or isolated IFG (WHO 1999) were re-invited after 1 and 3 years. Follow-up data on glucose measurements were available in 1,510 individuals and additional clinical data in 1,002 collected at the 3-year visits. Regression models using interval censoring were used. RESULTS: Progression rates from IFG and IGT to diabetes over 3.5 years were 11.8 and 17.0 per 100 person-years, respectively and were particularly high in the first year. Baseline determinants of progression were: IFG: glucose measures, BMI [per kg/m2, rate ratio (RR) 1.04 (95% CI, 1.01-1.08)] and triacylglycerol [per twofold increase, RR 2.19 (1.49-3.22)]; and IGT: glucose measures and known hypertension [RR 1.46 (1.11-1.93)]. Weight reduction and decreased triacylglycerol were inversely associated with development of diabetes in IFG individuals [per 1 kg/year, RR 0.81 (0.66-0.98) and per 1 mmol l(-1) year(-1), RR 0.08 (0.01-0.51), respectively], whereas in IGT participants only weight reduction was inversely associated [per 1 kg/year, RR 0.80 (0.67-0.96)]. CONCLUSIONS/ INTERPRETATION: Higher levels of glucose measures, larger BMI, known hypertension and hypertriacylglycerolaemia are significant determinants of progression in high-risk screened individuals. Weight loss of 1 kg/year or reduction of hypertriacylglycerolaemia markedly reduced the risk of diabetes.
Authors: X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard Journal: Diabetes Care Date: 1997-04 Impact factor: 19.112
Authors: Richard F Hamman; Edward Horton; Elizabeth Barrett-Connor; George A Bray; Costas A Christophi; Jill Crandall; Jose C Florez; Sarah Fowler; Ronald Goldberg; Steven E Kahn; William C Knowler; John M Lachin; Mary Beth Murphy; Elizabeth Venditti Journal: Diabetes Date: 2014-10-02 Impact factor: 9.461
Authors: Hyon-Suk Kim; Jaeseong Jo; Jung Eun Lim; Young Duk Yun; Soo Jin Baek; Tae-Yong Lee; Kap Bum Huh; Sun Ha Jee Journal: Endocrine Date: 2013-02-06 Impact factor: 3.633
Authors: A Heraclides; T M Jensen; S S Rasmussen; J Eugen-Olsen; S B Haugaard; K Borch-Johnsen; A Sandbæk; T Lauritzen; D R Witte Journal: Diabetologia Date: 2013-04-24 Impact factor: 10.122
Authors: Timo Saaristo; Leena Moilanen; Eeva Korpi-Hyövälti; Mauno Vanhala; Juha Saltevo; Leo Niskanen; Jari Jokelainen; Markku Peltonen; Heikki Oksa; Jaakko Tuomilehto; Matti Uusitupa; Sirkka Keinänen-Kiukaanniemi Journal: Diabetes Care Date: 2010-07-27 Impact factor: 19.112
Authors: E Ferrannini; M Massari; M Nannipieri; A Natali; R Lopez Ridaura; C Gonzales-Villalpando Journal: Diabetologia Date: 2009-02-18 Impact factor: 10.122